Abstract
Background
This study aimed to explore the correlation of circulating inflammatory cytokines’ levels with treatment response to etanercept (ETN) treatment in psoriasis patients.
Methods
97 moderate-to-severe plaque-psoriasis patients were continuously recruited in this prospective cohort study, and all patients received ETN treatment. Serum samples were collected before and at 6 months (M6) after treatment, and nine inflammatory cytokines expressions were detected by enzyme-linked immuno sorbent assay. Psoriasis Area and Severity Index (PASI) score was evaluated at baseline (M0), 1 month (M1), 3 months (M3) and M6 after treatment, and the corresponding PASI 75/90 responses’ rates were calculated.
Results
Tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-12, IL-17A, IL-22, IL-23, and IL-32 levels were reduced, while IL-10 level was elevated at M6 after ETN treatment compared to baseline. PASI 75/90 responses’ rates to ETN were 69.1 and 38.1% at M6, respectively. IL-1β and IL-17A levels were elevated in PASI 75-response patients compared to PASI 75 non-response patients, while IL-17A level was also increased in PASI 90-response patients compared to PASI 90 non-response patients. Multivariate logistic regression revealed that IL-1β, IL-17A and combined phototherapy during study predicted higher, while previous systemic biologic treatment predicted lower PASI 75 response to ETN independently. In addition, IL-17A independently predicted higher PASI 90 response to ETN as well.
Conclusions
IL-1β, IL-17A, and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to ETN independently in psoriasis patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boehncke WH, Schon MP (2015) Psoriasis. Lancet 386:983–994. https://doi.org/10.1016/S0140-6736(14)61909-7
Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P (2018) Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermatol Treat. https://doi.org/10.1080/09546634.2018.1467536
Di Lernia V et al (2018) Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatol Treat 29:217–219. https://doi.org/10.1080/09546634.2017.1364692
Fitz L et al (2018) Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol. https://doi.org/10.1111/ced.13561
Kanelleas A et al (2011) The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 36:845–850. https://doi.org/10.1111/j.1365-2230.2011.04131.x
Kivelevitch D, Mansouri B, Menter A (2014) Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics 8:169–182. https://doi.org/10.2147/BTT.S41481
Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.02.040
Motolese A, Chiaravalloti V, Cerati M, Oldrini R, Mola F, Passi A (2017) Interleukin levels and macrophagic density in periumbilical fat tissue in patients affected by moderate-to-severe psoriasis with metabolic syndrome, before and after etanercept treatment. G Ital Dermatol Venereol 152:342–347. https://doi.org/10.23736/S0392-0488.16.05235-4
Nakajima H, Nakajima K, Tarutani M, Morishige R, Sano S (2011) Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 303:451–455. https://doi.org/10.1007/s00403-011-1159-3
Paller AS et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358:241–251. https://doi.org/10.1056/NEJMoa066886
Prinz JC, Puig L, Girolomoni G (2016) Treatment of psoriasis with etanercept: the typical patient profile. J Eur Acad Dermatol Venereol JEADV 30:1092–1099. https://doi.org/10.1111/jdv.13662
Senra L, Stalder R, Alvarez Martinez D, Chizzolini C, Boehncke WH, Brembilla NC (2016) Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol 136:1970–1980. https://doi.org/10.1016/j.jid.2016.06.009
Shi R, Chen M, Litifu B (2018) Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol 28:126–132. https://doi.org/10.1080/14397595.2017.1317384
Sobhan MR, Farshchian M, Hoseinzadeh A, Ghasemibasir HR, Solgi G (2016) Serum levels of IL-10 and IL-22 cytokines in patients with psoriasis. Iran J Immunol 13(3):317–323
Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M, Fraser S (2017) Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J 19:1218–1222. https://doi.org/10.1208/s12248-017-0094-4
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159:322–330. https://doi.org/10.1111/j.1365-2133.2008.08628.x
Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H (2010) Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 35:645–649. https://doi.org/10.1111/j.1365-2230.2009.03704.x
Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB (2007) Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 12:38–45. https://doi.org/10.1038/sj.jidsymp.5650037
Tsai YC, Tsai TF (2017) Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis 9:277–294. https://doi.org/10.1177/1759720X17735756
Wang F et al (2012) Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol 167:92–102. https://doi.org/10.1111/j.1365-2133.2012.10961.x
Wasilewska A, Winiarska M, Olszewska M, Rudnicka L (2016) Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol 33:247–252. https://doi.org/10.5114/ada.2016.61599
Wolk K et al (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36:1309–1323. https://doi.org/10.1002/eji.200535503
Xie F et al (2017) Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. J Huazhong Univ Sci Technol Med Sci = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban 37:943–947. https://doi.org/10.1007/s11596-017-1832-7
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declared that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Liu, Y., Qin, G., Meng, Z. et al. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients. Inflammopharmacol 27, 57–66 (2019). https://doi.org/10.1007/s10787-018-0530-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-018-0530-9